Glaukos Corp (N:GKOS)

Business Focus: Medical Devices & Implants

Apr 16, 2024 04:05 pm ET

Glaukos Announces the Release of its 2023 Sustainability Report

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has published its 2023 Sustainability Report. The report highlights the company’s continued commitment and progress on its key corporate sustainability initiatives. The Sustainability Report can be found on the company’s website

Apr 10, 2024 07:00 am ET

Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2024 financial results after the market close on Wednesday, May 1, 2024. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on May 1, 2024.

Apr 03, 2024 07:00 am ET

Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the U.S. Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code for iDose® TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog indicated for the reduction of intraocular pressure (IOP) in patients with ocular hypertension (OHT) or open-angle glaucoma (OAG).

Apr 01, 2024 07:00 am ET

Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it will present multiple scientific abstracts at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held April 5-8, 2024 in Boston, MA. Glaukos will be exhibiting onsite at booth #631.

Feb 21, 2024 04:05 pm ET

Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results

Jan 31, 2024 07:00 am ET

Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2023 financial results after the market close on Wednesday, February 21, 2024. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on February 21, 2024.

Jan 09, 2024 07:00 am ET

Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Net Sales and Reaffirms 2024 Revenue Guidance

Dec 20, 2023 07:00 am ET

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 5:15 p.m. PT in San Francisco, CA.

Dec 14, 2023 07:00 am ET

Glaukos Announces FDA Approval of iDose® TR (travoprost intracameral implant)

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for a single administration per eye of iDose® TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog indicated for the reduction of intraocular pressure (IOP) in patients with ocular hypertension (OHT) or open-angle glaucoma (OAG).

Nov 07, 2023 07:00 am ET

Glaukos Announces Participation in Stifel Healthcare Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Stifel Healthcare Conference on Tuesday, November 14, 2023, at 10:55 a.m. ET in New York City.

Nov 01, 2023 04:05 pm ET

Glaukos Announces Third Quarter 2023 Financial Results

Oct 31, 2023 07:00 am ET

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Academy of Ophthalmology Annual Meeting

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being held November 3-6, 2023 in San Francisco, CA. Glaukos will be exhibiting onsite at booth #1630.

Oct 11, 2023 07:00 am ET

Glaukos to Release Third Quarter 2023 Financial Results after Market Close on November 1, 2023

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release third quarter 2023 financial results after the market close on Wednesday, November 1, 2023. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on November 1, 2023.

Aug 23, 2023 07:00 am ET

Glaukos Announces Participation in Wells Fargo Healthcare Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 6, 2023, at 12:45 p.m. ET in Boston, MA.

Aug 02, 2023 04:05 pm ET

Glaukos Announces Second Quarter 2023 Financial Results

Jul 17, 2023 07:00 am ET

Glaukos Enters into a Collaboration and Marketing Agreement with Radius XR, Inc.

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it has entered into a collaboration and marketing agreement with Radius XR, Inc., whereby Glaukos will become the exclusive sales agent to market, promote and solicit orders for the Radius XR™ wearable patient engagement and diagnostic system within the United States. Radius will continue to lead development and commercialization efforts for Radius XR.

Jul 12, 2023 07:00 am ET

Glaukos to Release Second Quarter 2023 Financial Results after Market Close on August 2, 2023

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2023 financial results after the market close on Wednesday, August 2, 2023. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on August 2, 2023.

Jun 05, 2023 07:00 am ET

Glaukos Achieves Pipeline Milestone with Enrollment Completion in Phase 3 Confirmatory Trial for Epioxa (Epi-on)

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the completion of enrollment and randomization in its second Phase 3 confirmatory pivotal trial for Epioxa™ (Epi-on), its next-generation corneal cross-linking therapy for the treatment of keratoconus.

May 24, 2023 07:00 am ET

Glaukos Announces Participation in the William Blair Growth Stock Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the William Blair 43rd Annual Growth Stock Conference on Wednesday, June 7, 2023, at 10:40 a.m. CT in Chicago, IL.

May 05, 2023 04:05 pm ET

Glaukos Announces FDA Acceptance of NDA Submission for iDose TR

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it has received the “Day 74” notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for iDose® TR (travoprost intraocular implant) is sufficiently complete to permit a substantive review. The Prescription Drug User Fee Act (PDUFA) goal date for the completion of the FDA’s review of the

May 03, 2023 04:05 pm ET

Glaukos Announces First Quarter 2023 Financial Results

May 01, 2023 07:00 am ET

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Society of Cataract and Refractive Surgery Annual Meeting

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held May 5 – 8, 2023 in San Diego, CA. Glaukos will be exhibiting onsite at booth #1237.

Apr 19, 2023 07:00 am ET

Glaukos Announces the Release of its 2022 Sustainability Report

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has published its 2022 Sustainability Report. The report highlights the company’s continued commitment and progress on environmental, social and governance (ESG) initiatives. The Sustainability Report can be found on the company’s website

Apr 12, 2023 07:00 am ET

Glaukos to Release First Quarter 2023 Financial Results after Market Close on May 3

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2023 financial results after the market close on Wednesday, May 3, 2023. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on May 3, 2023.

Feb 27, 2023 07:00 am ET

Glaukos Submits New Drug Application to U.S. FDA for iDose TR

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iDose® TR. iDose TR is a micro-invasive intraocular implant designed to continuously deliver therapeutic levels of a proprietary formulation of travoprost from within the eye for extended periods of time. iDose TR is intended to address ubiquitou

Feb 22, 2023 04:05 pm ET

Glaukos Announces Fourth Quarter and Full Year 2022 Financial Results

Feb 15, 2023 07:00 am ET

Glaukos Announces Participation in the Citi Healthcare Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Citi Healthcare Conference on Wednesday, March 1, 2023, at 1:15 p.m. ET in New York City.

Feb 01, 2023 07:00 am ET

Glaukos to Release Fourth Quarter and Full Year 2022 Financial Results after Market Close on February 22

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2022 financial results after the market close on Wednesday, February 22, 2023. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on February 22, 2023.

Jan 10, 2023 04:05 pm ET

Glaukos Announces Positive Clinical Updates for Several Corneal Health Pipeline Programs

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced positive clinical updates for several of its Corneal Health pipeline programs, including the commencement of subject enrollment in a second Phase 3 confirmatory trial for Epioxa™ (Epi-on™), and promising initial results from the company’s Phase 2a clinical trial for GLK-301 (iLution - Dry Eye Disease).

Jan 10, 2023 04:05 pm ET

Glaukos Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable Safety and Tolerability

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced positive results for a prospective, multi-center clinical trial designed to evaluate the safety of the surgical exchange procedure for iDose® TR (travoprost intraocular implant) in subjects who had previously been administered an iDose TR in the Phase 2b clinical trial (referred to as the “exchange trial”).

Dec 28, 2022 04:15 pm ET

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 41st Annual J.P Morgan Healthcare Conference on Tuesday, January 10, 2023, at 5:15 p.m. PT in San Francisco, CA.

Nov 07, 2022 07:00 am ET

Glaukos Announces Participation in the Stephens Annual Investment Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Stephens Annual Investment Conference on Wednesday, November 16, 2022, at 2:00 p.m. CT in Nashville, TN.

Nov 02, 2022 04:05 pm ET

Glaukos Corporation Announces Third Quarter 2022 Financial Results

Oct 12, 2022 07:00 am ET

Glaukos to Release Third Quarter 2022 Financial Results after Market Close on November 2

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release third quarter 2022 financial results after the market close on Wednesday, November 2, 2022. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on November 2, 2022.

Sep 28, 2022 07:00 am ET

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Academy of Ophthalmology Annual Meeting

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being held September 30 - October 3, 2022 in Chicago, IL.

Sep 07, 2022 07:00 am ET

Glaukos Announces Positive Topline Outcomes for Both Phase 3 Pivotal Trials of iDose TR, Achieving Primary Efficacy Endpoints and Demonstrating Favorable Tolerability and Safety Profiles

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced positive topline data for both Phase 3 pivotal trials of iDose TR that successfully achieved its pre-specified primary efficacy endpoints through 3 months in both Phase 3 trials and demonstrated excellent tolerability and a favorable safety profile through 12 months.

Sep 06, 2022 07:00 am ET

Glaukos Announces More Than 1 Million iStent® Technologies Implanted Worldwide

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced a significant milestone as its iStent® family of technologies have now been implanted in more than one million procedures worldwide. This market-leading milestone is a testament to the decades of investment from Glaukos as the corporate founder and pioneer of the now well-established micro-invasive glaucoma surgery (MIGS) marketplace.

Aug 29, 2022 03:55 pm ET

Burns & Levinson Represents iVeena Delivery Systems, Inc. in Strategic Licensing Agreement with Glaukos Corporation

BOSTON, Aug. 29, 2022 /PRNewswire/ -- – Burns & Levinson is pleased to announce that it represented iVeena Delivery Systems, Inc. (iVeena), a clinical stage biopharmaceutical company with developmental products in keratoconus and pediatric myopia, in a strategic licensing agreement with Glaukos Corporation (NYSE: GKOS). On August 24, iVeena announced that it has licensed its lead asset, IVMED-80, an Orphan Drug Designated eye drop for keratoconus to Glaukos. The agreement grants Glaukos an exclusive global license to develop and commercialize IVMED-80. As part of the agreement, Glaukos p

Aug 24, 2022 07:00 am ET

Glaukos Announces Participation in the Wells Fargo Healthcare Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 7, 2022, at 3:45 p.m. ET in Boston, MA.

Aug 03, 2022 04:05 pm ET

Glaukos Announces FDA 510(k) Clearance of iStent infinite®

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the iStent infinite® Trabecular Micro-Bypass System indicated for use in a standalone procedure to reduce elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma uncontrolled by prior medical and surgical therapy.

Aug 03, 2022 04:05 pm ET

Glaukos Corporation Announces Second Quarter 2022 Financial Results

Jul 13, 2022 07:00 am ET

Glaukos to Release Second Quarter 2022 Financial Results after Market Close on August 3

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2022 financial results after the market close on Wednesday, August 3, 2022. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on August 3, 2022.

Jun 02, 2022 07:00 am ET

Glaukos Announces Participation in the William Blair Growth Stock Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the William Blair 42nd Annual Growth Stock Conference on Wednesday, June 8, 2022, at 8:40 a.m. CT in Chicago, IL.

May 20, 2022 07:00 am ET

Glaukos Announces Participation in the Piper Sandler Virtual Ophthalmology Symposium

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the Piper Sandler Ophthalmology Symposium on Monday, May 23, 2022, at 2:00 p.m. ET.

May 04, 2022 04:05 pm ET

Glaukos Corporation Announces First Quarter 2022 Financial Results

Apr 21, 2022 07:00 am ET

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held April 22–26, 2022 in Washington, D.C.

Apr 20, 2022 07:00 am ET

Glaukos Announces the Release of its 2021 Sustainability Report

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has published its 2021 Sustainability Report. The report highlights the company’s continued commitment and progress on environmental, social and governance (ESG) initiatives. The Sustainability Report can be found on the company’s website

Apr 13, 2022 07:00 am ET

Glaukos to Release First Quarter 2022 Financial Results after Market Close on May 4

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2022 financial results after the market close on Wednesday, May 4, 2022. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on May 4, 2022.

Mar 14, 2022 07:00 am ET

Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Generation iLink™ Therapy

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has commenced a Phase 2 clinical program for its third-generation iLink™ therapy designed to treat keratoconus.

Feb 22, 2022 04:05 pm ET

Glaukos Corporation Announces Fourth Quarter and Full Year 2021 Financial Results

Feb 07, 2022 04:15 pm ET

Glaukos Announces Executive Leadership Changes

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced several executive leadership changes to support the company’s future growth and strategic plans. The following executive changes will become effective on April 1, 2022:

Feb 01, 2022 07:00 am ET

Glaukos Corporation to Release Fourth Quarter and Full Year 2021 Financial Results after Market Close on February 22

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2021 financial results after the market close on Tuesday, February 22, 2022. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PST (4:30 p.m. EST) on February 22, 2022.

Jan 11, 2022 04:10 pm ET

Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Dry Eye Disease

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has enrolled the first patient into a Phase 2 clinical trial of GLK-301 for the treatment of signs and symptoms of Dry Eye Disease (DED). GLK-301 is the first investigational drug candidate utilizing Glaukos’ iLution platform’s patented cream-based drug formulations that are applied to the outer surface of the eyelid for dropless transdermal delivery of pharmaceutically active comp

Jan 11, 2022 04:10 pm ET

Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Presbyopia

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has enrolled the first patient into a Phase 2 clinical trial of GLK-302 for the treatment of presbyopia. GLK-302 is the second investigational drug candidate utilizing Glaukos’ iLution platform’s patented cream-based drug formulations that are applied to the outer surface of the eyelid for dropless transdermal delivery of pharmaceutically active compounds for the treatment of eye d

Jan 11, 2022 04:10 pm ET

Glaukos’ iDose® TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 36 Months in Phase 2b Study

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its iDose® TR sustained-release travoprost implant continued to provide sustained substantial reductions in intraocular pressure (IOP) in a 36-month analysis of the 36-month Phase 2b clinical trial conducted under a U.S. Investigational New Drug (IND) protocol.

Jan 06, 2022 04:10 pm ET

Glaukos Announces FDA 510(k) Clearance of iPRIME™

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the iPRIME™ Viscodelivery System, a sterile, single-use, minimally-invasive device for the delivery of viscoelastic fluid during ophthalmic surgery.

Dec 29, 2021 07:00 am ET

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 5:15 p.m. ET.

Dec 20, 2021 04:15 pm ET

Glaukos Announces Retirement of William J. Link, Ph.D., as Chairman of the Board and Election of Thomas W. Burns as New Chairman and Mark J. Foley as Lead Independent Director

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that William J. Link, Ph.D., will be retiring as Chairman of the Board, effective December 31, 2021. Dr. Link joined Glaukos’ Board and has served as Chairman since June 2001. In connection with Dr. Link’s retirement, the Board has appointed Thomas W. Burns, Glaukos’ President and Chief Executive Officer and a director on the Board since 2002, to serve as the company’s Chairman of the Boar

Nov 19, 2021 07:00 am ET

Glaukos Announces Participation in Upcoming Investor Conferences

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the following upcoming investor conferences:

Nov 11, 2021 07:00 am ET

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 American Academy of Ophthalmology Annual Meeting

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today that its technologies will be highlighted in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being held November 12–15, 2021 in New Orleans, Louisiana.

Nov 04, 2021 04:10 pm ET

Glaukos Corporation Announces Third Quarter 2021 Financial Results

Oct 14, 2021 07:00 am ET

Glaukos Corporation to Release Third Quarter 2021 Financial Results after Market Close on November 4

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release third quarter 2021 financial results after the market close on Thursday, November 4, 2021. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on November 4, 2021.

Oct 07, 2021 04:15 pm ET

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 European Society of Cataract and Refractive Surgeons Annual Meeting

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the European Society of Cataract and Refractive Surgeons (ESCRS) Annual Meeting, being held October 8-11, 2021, in Amsterdam, Netherlands.

Sep 20, 2021 07:00 am ET

Glaukos Announces Licensing Agreement with Attillaps Holdings, Inc.

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it has entered into a licensing agreement with Attillaps Holdings, Inc. under which Attillaps has granted Glaukos a global exclusive license to research, develop, manufacture and commercialize Attillaps’ proprietary library of investigational pharmaceutical compounds that target the eradication of Demodex mites, which are the root cause of Demodex blepharitis and often associated with

Sep 15, 2021 07:00 am ET

Glaukos Announces Settlement of Patent Litigation with Ivantis, Inc.

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it has entered into a settlement agreement with Ivantis, Inc. agreeing to terminate the patent infringement lawsuit Glaukos initiated on April 14, 2018 in the U.S. District Court for the Central District of California, Southern Division, concerning Ivantis’ Hydrus® Microstent.

Sep 03, 2021 07:00 am ET

Glaukos Announces Submission of Supplemental Pre-Market Approval Application for iStent infinite™

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has submitted a supplemental pre-market approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the iStent infinite™ Trabecular Micro-Bypass System.

Aug 26, 2021 07:00 am ET

Glaukos Announces Participation in the Wells Fargo Healthcare Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the Wells Fargo Healthcare Conference on Thursday, September 9, 2021, at 2:40 p.m. ET.

Aug 23, 2021 07:00 am ET

Glaukos Announces Market-Leading Clinical Milestone of 200 Peer-Reviewed Publications on iStent® Technologies

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today an unprecedented clinical data milestone of 200 peer-reviewed publications highlighting the efficacy and safety of iStent® technologies around the world. This achievement represents the largest, most diverse and longest-term body of clinical data for any MIGS procedure. Several points of note in this market-leading body of clinical evidence include:

Aug 05, 2021 04:10 pm ET

Glaukos Corporation Announces Second Quarter 2021 Financial Results

Jul 22, 2021 07:00 am ET

Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 American Society of Cataract and Refractive Surgery Annual Meeting

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, being held July 23–27, 2021 in Las Vegas, Nevada.

Jul 15, 2021 04:15 pm ET

Glaukos Corporation to Release Second Quarter 2021 Financial Results after Market Close on August 5

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2021 financial results after the market close on Thursday, August 5, 2021. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on August 5, 2021.

Jul 14, 2021 02:00 am ET

Glaukos Comments on the Centers for Medicare and Medicaid Services 2022 Proposed Physician Fee Schedule

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today commented on the recently released Centers for Medicare and Medicaid Services (CMS) Calendar Year 2022 Medicare Physician Fee Schedule Proposed Rule. The Proposed Rule was released on July 13, 2021, and updates payment policies, payment rates and other provisions for services furnished under the Medicare Physician Fee Schedule on or after January 1, 2022. The Proposed Rule release is followed by a 6

Jun 10, 2021 07:00 am ET

Glaukos Achieves Pipeline Milestone with Completion of Patient Enrollment in U.S. NDA Phase 3 Clinical Trials for iDose® TR

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the completion of patient enrollment and randomization in its U.S. Food and Drug Administration (FDA) New Drug Application (NDA) Phase 3 clinical trials for the iDose® TR sustained-release travoprost implant.

Jun 08, 2021 07:00 am ET

Glaukos Announces Australia’s TGA Regulatory Approval for PRESERFLO™ MicroShunt

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that the Therapeutic Goods Administration (TGA) of Australia has granted regulatory approval for the PRESERFLO MicroShunt intended for the reduction of intraocular pressure (IOP) in eyes of patients with primary open-angle glaucoma where IOP remains uncontrollable while on maximum tolerated medical therapy and/or where glaucoma progression warrants surgery.

May 19, 2021 07:00 am ET

Glaukos Announces Participation in the William Blair 41st Annual Growth Stock Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the William Blair 41st Annual Growth Stock Conference on Wednesday, June 2, 2021, at 4:40 p.m. CDT.

May 18, 2021 06:00 pm ET

Glaukos Expands its PRESERFLO™ MicroShunt Relationship with Santen via New License Agreement

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has entered into a new development and commercialization license agreement with Santen Pharmaceutical Co., Ltd. (Santen) for the PRESERFLO™ MicroShunt (development code: DE-128), superseding the previous collaboration and distribution agreements between the two parties.

May 05, 2021 04:10 pm ET

Glaukos Corporation Announces First Quarter 2021 Financial Results

Apr 27, 2021 07:00 am ET

Glaukos Announces the Release of its 2020 Sustainability Report

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has published its 2020 Sustainability Report. The report highlights the company’s continued commitment and progress on environmental, social and governance (ESG) initiatives. The Sustainability Report can be found on the company’s website

Apr 22, 2021 07:00 am ET

Glaukos Announces Global Licensing Agreement Amendment with Intratus, Inc. to Include the Treatment of Presbyopia

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has entered into an amended licensing agreement with Intratus, Inc. under which Intratus has granted Glaukos a global exclusive license to research, develop, manufacture and commercialize Intratus’ patented, non-invasive drug delivery platform (the Eyelid Drug Delivery Platform) for application in the treatment of presbyopia.

Apr 14, 2021 04:15 pm ET

Glaukos Corporation to Release First Quarter 2021 Financial Results after Market Close on May 5

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2021 financial results after the market close on Wednesday, May 5, 2021. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on May 5, 2021.

Mar 08, 2021 07:00 am ET

Glaukos to Support World Glaucoma Week with Patient Education Campaign and Free Screening Initiatives

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced two new patient-centric initiatives in honor of World Glaucoma Week. World Glaucoma Week is an annual global initiative championed by the World Glaucoma Association (WGA) to raise awareness surrounding the risk and prevalence of glaucoma. As a proud sponsor of the WGA, Glaukos is launching a global education and awareness campaign and collaborating with eye care institutions across the Uni

Mar 02, 2021 07:00 am ET

Glaukos Announces Participation in Oppenheimer Healthcare Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the Oppenheimer 31st Annual Healthcare Conference on Tuesday, March 16, 2021, at 3:10 p.m. EDT.

Mar 01, 2021 04:10 pm ET

Glaukos Appoints Denice Torres and Dr. Leana Wen to its Board of Directors

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the appointment of Denice Torres and Dr. Leana Wen to its Board of Directors, effective today. With the addition of these two directors, Glaukos’ Board of Directors will be comprised of nine directors, eight of whom are independent.

Feb 25, 2021 04:10 pm ET

Glaukos Corporation Announces Fourth Quarter and Full Year 2020 Financial Results

Feb 25, 2021 04:05 pm ET

Glaukos Announces Positive Phase 3 Trial Results for iLink™ Epi-on Investigational Therapy That Met the Primary Efficacy Endpoint

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that U.S. Phase 3 pivotal trial results for its next-generation corneal cross-linking iLink™ therapy for the treatment of keratoconus, known as Epi-on, met the study’s primary efficacy endpoint, demonstrating a statistically significant improvement in maximum corneal curvature (Kmax) at 6 months from baseline between the treated and placebo-controlled arms. Kmax is an objective measurement

Feb 04, 2021 07:00 am ET

Glaukos Corporation to Release Fourth Quarter and Full Year 2020 Financial Results after Market Close on February 25

A link to the live webcast will be available on the company’s website at http://investors.glaukos.com. To participate in the conference call, please dial 833-231-8262 (U.S.) or 647-689-4107 (International) and enter Conference ID 4167849. A replay will be archived on the company’s website following completion of the call.

Jan 13, 2021 07:00 am ET

Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2020 Net Sales

Jan 13, 2021 07:00 am ET

Glaukos’ iDose® TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 24 Months in Phase 2b Study

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its iDose® TR sustained-release travoprost implant continued to provide sustained substantial reductions in intraocular pressure (IOP) in a 24-month interim analysis of the ongoing 36-month Phase 2b clinical trial conducted under a U.S. Investigational New Drug (IND) protocol.

Jan 13, 2021 07:00 am ET

U.S. IDE Trial Results for Glaukos’ iStent infinite™ Show Substantial Reduction in IOP

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that 12-month U.S. Investigational Device Exemption (IDE) pivotal trial data showed that its iStent infinite™ Trabecular Micro-Bypass System achieved a substantial reduction in mean diurnal intraocular pressure (IOP) in patients with open-angle glaucoma uncontrolled by prior surgical or medical therapy.

Dec 23, 2020 07:00 am ET

Glaukos Announces Participation in J.P. Morgan Healthcare Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021, at 11:00 a.m. PST.

Nov 11, 2020 04:15 pm ET

Glaukos Announces Participation in Upcoming Investor Conferences

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the following upcoming investor conferences:

Nov 05, 2020 04:10 pm ET

Glaukos Corporation Announces Third Quarter 2020 Financial Results

Oct 15, 2020 07:00 am ET

Glaukos Corporation to Release Third Quarter 2020 Financial Results after Market Close on November 5

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release third quarter 2020 financial results after the market close on Thursday, November 5, 2020. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PST (4:30 p.m. EST) on November 5, 2020.

Sep 09, 2020 09:48 am ET

INVESTIGATION ALERT: Nationally Ranked Litigation Firm Labaton Sucharow Announces Investigation of the Merger of Avedro, Inc. and Glaukos Corporation and Strongly Encourages Investors to Contact the F

Labaton Sucharow LLP, a leading investor rights law firm, announces it is investigating potential securities claims on behalf of former shareholders of Avedro Inc. (NASDAQ: AVDR) concerning allegations that Glaukos Corp. (NASDAQ: GKOS), may have issued materially misleading business information to the investing public in connection with its November 2019 merger with Avedro.

Sep 08, 2020 09:44 am ET

INVESTIGATION ALERT: Nationally Ranked Litigation Firm Labaton Sucharow Announces Investigation of the Merger of Avedro, Inc. and Glaukos Corporation and Strongly Encourages Investors to Contact the F

Sep 04, 2020 07:00 am ET

Glaukos Announces Participation in September Investor Conferences

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the following upcoming investor conferences:

Aug 06, 2020 04:10 pm ET

Glaukos Corporation Announces Second Quarter 2020 Financial Results

Jul 20, 2020 07:00 am ET

Glaukos Corporation to Release Second Quarter 2020 Financial Results after Market Close on August 6

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2020 financial results after the market close on Thursday, August 6, 2020. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on August 6, 2020.

Jun 09, 2020 06:30 pm ET

Glaukos Announces Presentation Cancellation at the William Blair 40th Annual Growth Stock Conference

About Glaukos

Jun 08, 2020 10:42 pm ET

Glaukos Corporation Announces Pricing of Private Offering of $250 Million of 2.75% Convertible Senior Notes

Glaukos Corporation (NYSE: GKOS) (the “Company” or “Glaukos”), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today the pricing of its private offering of $250 million aggregate principal amount of 2.75% Convertible Senior Notes due 2027 (the “notes”). The offering size was increased from the previously announced offering size of $200 million aggregate principal amount of notes. The notes were offered only to qualified institutional buyers in accordance with Rule 144A under

Jun 08, 2020 07:06 am ET

Glaukos Corporation Announces Proposed Private Offering of $200 Million of Convertible Senior Notes

Glaukos Corporation (NYSE: GKOS) (the “Company” or “Glaukos”), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it intends to offer, subject to market and other conditions, $200 million aggregate principal amount of Convertible Senior Notes due 2027 (the “notes”) in a private offering. The notes will be offered only to qualified institutional buyers in accordance with Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Glaukos expects to g

Jun 02, 2020 04:30 pm ET

Glaukos Announces Participation in the William Blair 40th Annual Growth Stock Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the William Blair 40th Annual Growth Stock Conference on Wednesday, June 10, 2020, at 3:20 p.m. CDT.

May 15, 2020 08:00 am ET

Glaukos Technologies Featured in Numerous Presentations at the 2020 American Society of Cataract and Refractive Surgery Virtual Annual Meeting

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various “on demand” presentations at the American Society of Cataract and Refractive Surgery (ASCRS) Virtual Annual Meeting, which will be held online on May 16-17, 2020.

May 07, 2020 04:10 pm ET

Glaukos Corporation Announces First Quarter 2020 Financial Results

Apr 21, 2020 08:30 am ET

Glaukos Corporation to Release First Quarter 2020 Financial Results after Market Close on May 7

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2020 financial results after the market close on Thursday, May 7, 2020. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on May 7, 2020.

Apr 09, 2020 09:00 am ET

Glaukos Provides Update on COVID-19 Impact and Preliminary Net Sales Range for the First Quarter of 2020

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today provided an update on the impact of the COVID-19 pandemic on the company and announced a preliminary net sales range for its first quarter of 2020.

Mar 24, 2020 09:00 am ET

Glaukos Provides COVID-19 Pandemic Update

Feb 27, 2020 04:15 pm ET

Glaukos Corporation Announces Fourth Quarter and Full Year 2019 Financial Results

Feb 26, 2020 04:30 pm ET

Numerous Presentations to Showcase Long-Term Efficacy & Safety of Glaukos Technologies at 2020 American Glaucoma Society Meeting

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retina diseases, announced today that its products will be featured in various presentations at the American Glaucoma Society (AGS) Annual Meeting beginning February 27, 2020 at the Gaylord National Resort & Convention Center in Washington D.C.

Feb 06, 2020 04:15 pm ET

Glaukos Corporation to Release Fourth Quarter and Full Year 2019 Financial Results after Market Close on February 27

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2019 financial results after the market close on Thursday, February 27, 2020. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PST (4:30 p.m. EST) on February 27, 2020.

Jan 03, 2020 07:15 am ET

Glaukos Announces Participation in J.P. Morgan Healthcare Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020, at 8:00 a.m. PST in San Francisco.

Nov 21, 2019 08:43 am ET

Glaukos Completes Acquisition of Avedro, Inc.

Nov 20, 2019 04:15 pm ET

Glaukos Announces Participation in Piper Jaffray Healthcare Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019, at 2:30 p.m. EST in New York City.

Nov 06, 2019 04:10 pm ET

Glaukos Corporation Announces Third Quarter 2019 Financial Results

Oct 30, 2019 04:15 pm ET

Glaukos Announces Participation in Stephens Investor Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Stephens Investor Conference on Wednesday, November 13, 2019, at 2:30 p.m. CST in Nashville, TN.

Oct 22, 2019 04:15 pm ET

Glaukos Corporation to Release Third Quarter 2019 Financial Results after Market Close on November 6

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release third quarter 2019 financial results after the market close on Wednesday, November 6, 2019. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PST (4:30 p.m. EST) on November 6, 2019.

Oct 10, 2019 07:00 am ET

Glaukos Achieves Pipeline Milestone with Completion of Patient Enrollment in U.S. IDE Trial for iStent infinite™

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the completion of patient enrollment in its U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) trial for the iStent infinite™ Trabecular Micro-Bypass System.

Oct 09, 2019 04:15 pm ET

Glaukos Products to be Subject of Multiple Presentations at American Academy of Ophthalmology Annual Meeting

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its products will be included in various presentations at the American Academy of Ophthalmology (AAO) annual meeting, which begins Saturday, October 12, 2019

Oct 08, 2019 04:15 pm ET

Glaukos’ iStent inject® Delivers Greater IOP Reduction vs. iStent® According to Newly Published Case Series

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that an independent, international case series published in Ophthalmology and Therapy showed that iStent inject® Trabecular Micro-Bypass System achieved a greater absolute intraocular pressure (IOP) reduction and a higher medication-free rate at one year postoperative, compared to the first-generation iStent® Trabecular Micro-Bypass Stent. All sub

Sep 19, 2019 12:51 pm ET

SEMG, PVTL, FCSC and AVDR SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts

Rigrodsky & Long, P.A. announces that it is investigating: SemGroup Corporation (NYSE: SEMG) regarding possible breaches of fiduciary duties and other violations of law related to SemGroup’s agreement to be acquired by Energy Transfer LP....

Sep 13, 2019 07:00 am ET

Multiple Presentations to Showcase Glaukos Products at 2019 European Society of Cataract and Refractive Surgeons Congress

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its products will be included in various presentations at the 37th Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), which begi

Aug 27, 2019 04:15 pm ET

Glaukos Announces Participation in Wells Fargo Healthcare Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 4, 2019, at 3:35 p.m. EDT in Boston, MA.

Aug 13, 2019 12:32 pm ET

TRCB, AVDR, CBM, and NCI SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts

Rigrodsky & Long, P.A. announces that it is investigating: Two River Bancorp (NASDAQ GM: TRCB) regarding possible breaches of fiduciary duties and other violations of law related to Two River’s agreement to be acquired by OceanFirst Financial...

Aug 08, 2019 02:03 pm ET

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Avedro, Inc.

NEW YORK, Aug. 8, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Avedro, Inc. (NASDAQ: AVDR) and its board of directors for breach of fiduciary duty concerning the proposed acquisition of the company by Glaukos Corporation (NYSE: GKOS). Stockholders will receive 0.365 shares of Glaukos Corporation common stock for each share of Avedro, Inc. stock that they hold. The transaction is valued at approximately $395 million and is expected to close in the fourth quarter of 2019.

Aug 08, 2019 11:32 am ET

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Avedro, Inc. to Glaukos Corporation is Fair to Shareholders

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Avedro, Inc. (“Avedro” or the “Company”) (NASDAQGM: AVDR) stock prior to August 7, 2019. You are hereby notified that Levi & Korsinsky,...

Aug 07, 2019 04:15 pm ET

Glaukos Corporation Announces Second Quarter 2019 Financial Results

Aug 07, 2019 04:10 pm ET

Glaukos and Avedro Announce Definitive Acquisition Agreement

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, and Avedro, Inc. (Nasdaq: AVDR), a leading hybrid ophthalmic pharmaceutical and medical technology company focused on treating corneal disease and disorders, today announced that the companies have entered into a definitive merger agreement under which Glaukos will acquire Avedro in an all-stock transaction. The transaction, which is subject to Avedro stockholder approval along with other customary closin

Jul 22, 2019 07:00 am ET

Glaukos Announces Global Licensing Agreement With Intratus, Inc.

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it has entered into a licensing agreement with Intratus, Inc. under which Intratus has granted Glaukos a global exclusive license to research, develop, manufacture and commercialize Intratus’ patented, non-invasive drug delivery platform designed for use in the treatment of dry eye disease, glaucoma and other corneal disorders, such as allergy, blepharitis, conjunctivitis and related

Jul 22, 2019 07:00 am ET

Glaukos Corporation to Release Second Quarter 2019 Financial Results after Market Close on August 7

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2019 financial results after the market close on Wednesday, August 7, 2019. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on August 7, 2019.

Jun 27, 2019 04:15 pm ET

Glaukos Corporation Completes Acquisition of DOSE Medical Corporation

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel ophthalmic surgical devices and sustained pharmaceutical therapies, announced today that it has successfully completed the acquisition of DOSE Medical Corporation that was previously announced on June 19, 2019. With the transaction’s completion, DOSE Medical has now become a wholly owned subsidiary of Glaukos.

Jun 19, 2019 04:15 pm ET

Glaukos Corporation Enters into Definitive Agreement to Acquire DOSE Medical Corporation

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel ophthalmic surgical devices and sustained pharmaceutical therapies, announced today that it has entered into a definitive Agreement and Plan of Merger to acquire DOSE Medical Corporation (DOSE Medical) for $2.5 million in cash, plus performance-based consideration upon achievement of certain regulatory approvals and commercial milestones. Upon the consummation of the acquisition, DOSE Medical wil

Jun 04, 2019 04:15 pm ET

International Study Confirms Significant, Sustained IOP and Medication Reduction Following Standalone Implantation of Glaukos’ iStent inject® in Glaucoma Patients with Substantial Disease Burden

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that results of an independent, international study published in Advances in Therapy showed standalone implantation of the iStent inject® Trabecular Micro-Bypass System in eyes with substantial glaucoma disease burden achieved a 42% reduct

May 22, 2019 04:15 pm ET

Glaukos Announces Participation in William Blair Growth Stock Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the William Blair Growth Stock Conference on Wednesday, June 5, 2019, at 8:00 a.m. CDT in Chicago, IL.

May 08, 2019 04:10 pm ET

Glaukos Corporation Announces First Quarter 2019 Financial Results

May 01, 2019 04:15 pm ET

Multiple Surgeons to Present Data on Glaukos Technologies at 2019 American Society of Cataract and Refractive Surgery

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that numerous surgeons will present clinical trial and real-world data regarding it products at the American Society of Cataract and Refractory Surgery (ASCRS) Annual Meeting on May 3-7, 2019 at the San Diego Convention Center in downtown San Diego, CA.

Apr 30, 2019 07:00 am ET

Glaukos Announces Participation in Bank of America Merrill Lynch 2019 Health Care Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the Bank of America Merrill Lynch 2019 Health Care Conference on Tuesday, May 14, 2019, at 3:40 p.m. PDT in Las Vegas, Nevada.

Apr 26, 2019 03:05 am ET

Santen and Glaukos Enter into Collaboration and Distribution Agreement for Exclusive Distribution of the MicroShunt (DE-128) in the United States

Santen Pharmaceutical Co., Ltd. (“Santen” TSE: 4536) and Glaukos Corporation (“Glaukos” NYSE: GKOS), announced today that Santen’s U.S. subsidiary, Santen Inc., has entered into a multi-year agreement whereby Glaukos will become the exclusive distributor of the MicroShunt (development code: DE-128) solely in the U.S. market.

Apr 17, 2019 04:15 pm ET

Glaukos Corporation to Release First Quarter 2019 Financial Results after Market Close on May 8

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, plans to release first quarter 2019 financial results after the market close on Wednesday, May 8, 2019. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on May 8, 2019.

Apr 15, 2019 07:00 am ET

Prospective, Randomized Trial Highlights 5-Year Performance of 2 Standalone Glaukos iStents® vs. Topical Prostaglandin in Newly Diagnosed Glaucoma Patients

Glaukos Corporation (NYSE:GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that results of an international glaucoma study published in Ophthalmology Glaucoma showed standalone implantation of two iStent® Trabecular Micro-Bypass Stents in newly diagnosed primary open-angle glaucoma (POAG) eyes achieved a 35

Apr 01, 2019 07:15 am ET

New Research: Key Drivers of Growth for Fresh Del Monte Produce, Baker Hughes, a GE company, HollyFrontier, Glaukos, HCI Group, and Revance Therapeutics — Factors of Influence, Major Initiatives and S

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Fresh Del Monte Produce, Inc. (NYSE:FDP), Baker Hughes, a GE company...

Mar 15, 2019 07:00 am ET

Pivotal Trial Results for Glaukos’ iStent inject® Published in Leading Ophthalmic Journal

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that the U.S. Investigational Device Exemption (IDE) pivotal trial results for its next-generation iStent inject® Trabecular Micro-Bypass System have been published in Ophthalmology.

Mar 13, 2019 04:15 pm ET

Glaukos Technologies Featured in Numerous Presentations at 2019 American Glaucoma Society Meeting

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that its products will be featured in various presentations at the American Glaucoma Society (AGS) Annual Meeting on March 14-17, 2019 at the Marriott Marquis Hotel in San Francisco.

Mar 12, 2019 04:15 pm ET

International Glaucoma Study Confirms Long-term Efficacy and Safety Profile of Glaukos iStent® Implantation in Combination with Cataract Surgery

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that results of an international glaucoma study published in the Journal of Cataract and Refractive Surgery showed use of iStent® Trabecular Micro-Bypass Stent during cataract surgery delivered a 38% reduction in mean intraocular pr

Feb 27, 2019 04:10 pm ET

Glaukos Corporation Announces Fourth Quarter and Full Year 2018 Financial Results

Feb 06, 2019 04:15 pm ET

Glaukos Corporation to Release Fourth Quarter and Full Year 2018 Financial Results after Market Close on February 27

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, plans to release fourth quarter and full year 2018 financial results after the market close on Wednesday, February 27, 2019. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PST (4:30 p.m. EST) on February 27, 2019.

Dec 19, 2018 04:15 pm ET

Glaukos Announces Participation in J.P. Morgan Healthcare Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019, at 9:30 a.m. PST in San Francisco.

Dec 11, 2018 04:15 pm ET

Glaukos iStent inject® Implantation with Concomitant Cataract Surgery Provides Sustained Reduction in IOP and Medication Burden, According to New Study

Nov 27, 2018 07:45 am ET

Consolidated Research: 2018 Summary Expectations for The Hackett Group, Green Plains, Malibu Boats, Hawaiian Electric Industries, Iridium Communications, and Glaukos — Fundamental Analysis, Key Perfor

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The Hackett Group, Inc. (NASDAQ:HCKT), Green Plains, Inc. (NASDAQ:GPRE),...

Nov 14, 2018 04:15 pm ET

Glaukos Announces Participation in Piper Jaffray Healthcare Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the Piper Jaffray Healthcare Conference on Wednesday, November 28, 2018, at 10:00 a.m. EST in New York City.

Nov 07, 2018 04:10 pm ET

Glaukos Corporation Announces Third Quarter 2018 Financial Results

Oct 26, 2018 07:00 am ET

Glaukos Technologies Featured in Presentations at 2018 American Academy of Ophthalmology Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that its products will be featured in various presentations at the American Academy of Ophthalmology (AAO) Annual Meeting on October 27-30, 2018 at McCormick Place in Chicago, IL.

Oct 17, 2018 07:00 am ET

Glaukos Corporation to Release Third Quarter 2018 Financial Results after Market Close on November 7

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, plans to release third quarter 2018 financial results after the market close on Wednesday, November 7, 2018. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PST (4:30 p.m. EST) on November 7, 2018.

Oct 15, 2018 08:10 am ET

Detailed Research: Economic Perspectives on DDR, Acuity Brands, Douglas Emmett, Glaukos, US Ecology, and Lear — What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of DDR Corp. (NYSE:DDR), Acuity Brands Inc (NYSE:AYI), Douglas Emmett, Inc....

Sep 21, 2018 07:00 am ET

Multiple Surgeon Presentations to Showcase Glaukos Products at 2018 European Society of Cataract and Refractive Surgeons Congress

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, announced today that its products will be included in various physician presentations at the 36th Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) on September 22-26, 2018, at the Messe Wien Exhibition and Congress Center in Vienna, Austria.

Aug 22, 2018 04:15 pm ET

Glaukos Announces Participation in Wells Fargo Healthcare Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 5, 2018, at 1:15 p.m. EDT in Boston, MA.

Aug 14, 2018 07:40 am ET

Investor Expectations to Drive Momentum within American Vanguard, Glaukos, United Natural Foods, Walker & Dunlop, Unisys, and Comfort Systems — Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of American Vanguard Corporation (NYSE:AVD), Glaukos Corporation (NYSE:GKOS),...

Aug 02, 2018 04:15 pm ET

Glaukos Announces Pharmaceutical Development Agreement with D. Western Therapeutics Institute, Inc.

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced it has entered into a research and development collaboration agreement with D. Western Therapeutics Institute (DWTI), a Japanese biotechnology company focused on the discovery and development of innovative new drugs to serve patients worldwide.

Aug 02, 2018 04:15 pm ET

Glaukos Corporation Announces Second Quarter 2018 Financial Results

Jul 19, 2018 07:00 am ET

Glaukos Corporation to Release Second Quarter 2018 Financial Results after Market Close on August 2

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, plans to release second quarter 2018 financial results after the market close on Thursday, August 2, 2018. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on August 2, 2018.

Jun 25, 2018 07:00 am ET

Glaukos Announces FDA Approval for the iStent inject® Trabecular Micro-Bypass System

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced it has received premarket approval (PMA) from the U.S. Food and Drug Administration (FDA) for the iStent inject® Trabecular Micro-Bypass System indicated for the reduction of intraocular pressure (IOP) in adult mild-to-moderate primary ope

May 30, 2018 04:15 pm ET

Glaukos Announces Participation in William Blair Growth Stock Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the William Blair Growth Stock Conference on Tuesday, June 12, 2018, at 2:50 p.m. CDT in Chicago, IL.

May 16, 2018 08:20 am ET

New Research Coverage Highlights Ellie Mae, Micron Technology, Applied Optoelectronics, Acadia Realty Trust, Glaukos, and Noble Energy — Consolidated Revenues, Company Growth, and Expectations for 201

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ellie Mae, Inc. (NYSE:ELLI), Micron Technology, Inc. (NASDAQ:MU), Applied...

May 09, 2018 04:15 pm ET

Glaukos Corporation Announces First Quarter 2018 Financial Results

May 02, 2018 07:00 am ET

Glaukos Announces Participation in Bank of America Merrill Lynch 2018 Health Care Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the Bank of America Merrill Lynch 2018 Health Care Conference on Wednesday, May 16, 2018, at 3:00 p.m. PDT in Las Vegas, Nevada.

Apr 19, 2018 04:30 pm ET

Glaukos Corporation to Release First Quarter 2018 Financial Results after Market Close on May 9

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, plans to release first quarter 2018 financial results after the market close on Wednesday, May 9, 2018. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on May 9, 2018.

Apr 14, 2018 03:30 pm ET

IDE Pivotal Trial Results for Glaukos’ iStent inject® Show Significant Reductions in Unmedicated IOP in Glaucoma Subjects Undergoing Cataract Surgery

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that two-year U.S. Investigational Device Exemption (IDE) pivotal trial data showed that its iStent inject® Trabecular Micro-Bypass System achieved a statistically significant reduction in unmedicated diurnal intraocular pressure (IOP) in patients undergoing cataract surgery.

Apr 14, 2018 08:00 am ET

Glaukos Files Patent Infringement Lawsuit Against Ivantis, Inc.

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that it has filed a patent infringement lawsuit against Ivantis, Inc. in the U.S. District Court for the Central District of California, Southern Division. The lawsuit alleges that Ivantis’ Hydrus Microstent device infringes Glaukos patents relating to certain of Glaukos’ core glaucoma technologies.

Apr 11, 2018 07:00 am ET

Multiple Surgeon Presentations to Include Glaukos Technologies at 2018 American Society of Cataract and Refractive Surgery

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, announced today that its products will be included in various physician presentations at the American Society of Catara

Mar 02, 2018 07:00 am ET

Glaukos Announces Participation in 30th Annual ROTH Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the 30th Annual ROTH Conference on Monday, March 12, 2018, at 10:00 a.m. PDT in Laguna Niguel, California.

Feb 28, 2018 04:10 pm ET

Glaukos Corporation Announces Fourth Quarter and Full Year 2017 Financial Results

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced financial results for the fourth quarter and full year ended December 31, 2017. Key highlights include:

Feb 27, 2018 04:30 pm ET

Glaukos Technologies Featured in Numerous Presentations at 2018 American Glaucoma Society Meeting

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, announced today that its products will be featured in numerous presentations at the 28th Annual Meeting of t

Feb 27, 2018 07:00 am ET

International Study Shows Long-Term Titrated IOP Control with 1, 2 or 3 Glaukos iStent® Trabecular Micro-Bypass Stents in Open-Angle Glaucoma Patients

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that, according to a study published in Clinical Ophthalmology, implantation of one, two or three iStent® Trabecular Micro-Bypass Stents achieved mean unmedicated intraocular pressure (IOP) reductions of 30%, 37% and 43%, respectively, at 36 months postoperative.

Feb 13, 2018 08:10 am ET

Detailed Research: Economic Perspectives on Omega Healthcare Investors, Vanda Pharmaceuticals, Acushnet, Prospect Capital, Intercontinental Exchange, and Glaukos — What Drives Growth in Today's Compet

NEW YORK, Feb. 13, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Omega Healthcare Investors, Inc. (NYSE:OHI), Vanda...

Feb 08, 2018 07:00 am ET

Glaukos iStent® Trabecular Micro-Bypass Stent Reduced IOP and Lowered Medication Burden in Patients with Severe Glaucoma, According to New Study

Feb 07, 2018 07:00 am ET

Glaukos Corporation to Release Fourth Quarter and Full Year 2017 Financial Results after Market Close on February 28

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, plans to release fourth quarter and full year 2017 financial results after the market close on Wednesday, February 28, 2018. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PST (4:30 p.m. EST) on February 28, 2018.

Jan 10, 2018 07:00 am ET

Glaukos Corporation’s iDose™ Travoprost Achieves Sustained IOP Reduction and Favorable Safety Profile in 12-Month Interim Cohort

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that its Travoprost Intraocular Implant with the iDose™ delivery system continued to provide sustained reduction in intraocular pressure (IOP) in a 12-month interim cohort of patients in its U.S. Investigational New Drug (IND) Phase II clinical trial.

Jan 03, 2018 07:00 am ET

Glaukos Submits IDE Application to FDA to Study iStent infinite™ Trabecular Micro-Bypass System

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that it has submitted an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) seeking authorization to study its iStent infinite™ Trabecular Micro-Bypass System.

Dec 27, 2017 04:30 pm ET

Glaukos Announces Participation in J.P. Morgan Healthcare Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018, at 9:00 a.m. PST in San Francisco.

Dec 27, 2017 07:00 am ET

Glaukos Announces Submission of Pre-Market Approval Application for the iStent Inject® Trabecular Micro-Bypass

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that it has submitted a pre-market approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the iStent inject® Trabecular Micro-Bypass Stent.

Dec 19, 2017 07:00 am ET

Glaukos to Begin Randomized U.S. IDE Pivotal Clinical Trial for the iStent SA™ System

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that the U.S. Food and Drug Administration (FDA) is allowing the company to move forward with a U.S. Investigational Device Exemption (IDE) pivotal study of its iStent SA™ Trabecular Micro-Bypass System.

Nov 30, 2017 07:00 am ET

Glaukos Announces Issuance of New U.S. Patent

Nov 27, 2017 07:30 am ET

Research Report Identifies Walker & Dunlop, Vanda Pharmaceuticals, Acushnet, SS&C Technologies, ManpowerGroup, and Glaukos with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

NEW YORK, Nov. 27, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Walker & Dunlop, Inc. (NYSE:WD), Vanda...

Nov 07, 2017 04:15 pm ET

Glaukos Corporation Announces Third Quarter 2017 Financial Results

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced financial results for the third quarter ended September 30, 2017. Key highlights include:

Oct 31, 2017 07:00 am ET

Glaukos Announces Participation in Stifel 2017 Healthcare Conference

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the Stifel 2017 Healthcare Conference on Tuesday, November 14, 2017, at 10:15 a.m. EST in New York City.

Oct 24, 2017 07:00 am ET

Glaukos Corporation to Release Third Quarter 2017 Financial Results after Market Close on November 7

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, plans to release third quarter 2017 financial results after the market close on Tuesday, November 7, 2017. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PST (4:30 p.m. EST) on November 7, 2017.

Oct 05, 2017 04:45 pm ET

Glaukos iStent® Products to be Showcased at 2017 European Society of Cataract and Refractive Surgery

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, announced today that various Key Opinion Leader (KOL) presentations and electronic posters will feature its iStent® Trabecular Micro-Bypass and iStent inject® Trabecular Micro-Bypass products at the upcoming European Society of Cataract and Refractive Surgery (ESCRS) annual